Gardner Lewis Asset Management L P Has $10.41 Million Position in Surmodics, Inc. (NASDAQ:SRDX)

Gardner Lewis Asset Management L P grew its position in shares of Surmodics, Inc. (NASDAQ:SRDX) by 23.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 262,878 shares of the company’s stock after purchasing an additional 49,944 shares during the quarter. Surmodics makes up 2.5% of Gardner Lewis Asset Management L P’s holdings, making the stock its 15th biggest holding. Gardner Lewis Asset Management L P’s holdings in Surmodics were worth $10,410,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its position in Surmodics by 19.2% in the 3rd quarter. State Street Corp now owns 374,068 shares of the company’s stock valued at $14,506,000 after acquiring an additional 60,240 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in Surmodics in the third quarter valued at $6,593,000. Charles Schwab Investment Management Inc. increased its holdings in Surmodics by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 117,904 shares of the company’s stock valued at $4,669,000 after purchasing an additional 1,593 shares during the period. Boussard & Gavaudan Investment Management LLP bought a new position in Surmodics during the 4th quarter worth $3,899,000. Finally, Barclays PLC lifted its holdings in Surmodics by 16.0% during the 3rd quarter. Barclays PLC now owns 88,750 shares of the company’s stock worth $3,443,000 after buying an additional 12,271 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Trading Up 0.4 %

Shares of SRDX stock opened at $30.61 on Friday. The company has a market cap of $437.60 million, a P/E ratio of -30.31 and a beta of 1.19. Surmodics, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The stock has a 50 day simple moving average of $32.99 and a two-hundred day simple moving average of $36.83. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. Research analysts forecast that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. Lake Street Capital upgraded shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Friday, March 7th. Finally, StockNews.com started coverage on shares of Surmodics in a research note on Monday, February 3rd. They issued a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).